Healthcare >> CEO Interviews >> June 2, 2003
DR. PAUL A. FRIEDMAN has been Chief Executive Officer of Incyte
Corporation since November 2001. Prior to joining Incyte, Dr.
Friedman was President of R&D for DuPont Pharmaceuticals Research
Laboratories (formerly The DuPont Merck Pharmaceutical Company).
Before joining DuPont, he ran discovery at Merck's West Point,
Pennsylvania site and had responsibility for worldwide safety
assessment and drug metabolism and pharmacokinetics. Dr. Friedman
played a major role in the development and commercialization of:
Aggrastat, Trusopt/Cosopt, Crixivan, Sustiva, Cozaar/Hyzaar,
Fosamax, Pedvax HIB, Pneumovax, Vaqta, and Varivax. Prior to
joining Merck, Dr. Friedman was an Associate Professor of
Clinical Pharmacology at Harvard Medical School and is Board
Certified in internal medicine and hematology. Profile
Dr. Friedman: Incyte is recognized as a genomic tool company.
It's a company that has developed and provides a terrific set
